Breton Roussel, MD
Gastroenterology · Providence, RINPI 1215385661
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,414 of the $49,888 with a category attached, or 81.0%. 22 manufacturers reported payments, led by Johnson & Johnson at 59.5% of the total. 2025 is the largest year on record at $39,661, more than ten times the $58 reported in 2020. Among gastroenterology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $170.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$30K
- Phathom Pharmaceuticals, Inc.$16K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$683
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$524
- Intercept Pharmaceuticals, Inc.$339
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$40,41481%
- Travel & lodging$1,9534%
- Food & beverage$7,52115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 55 | $29,703 |
| Phathom Pharmaceuticals, Inc. | 32 | $15,551 |
| AbbVie | 71 | $1,154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $683 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $524 |
| Intercept Pharmaceuticals, Inc. | 13 | $339 |
| Medtronic | 2 | $255 |
| Ardelyx, Inc. | 10 | $231 |
| Gilead | 13 | $230 |
| Bristol Myers Squibb | 9 | $207 |
| Pfizer | 9 | $179 |
| Lilly USA, LLC | 7 | $158 |
| Braintree Laboratories, Inc. | 2 | $151 |
| Novo Nordisk | 3 | $150 |
| Ironwood Pharmaceuticals, Inc | 5 | $97 |
| Ipsen Biopharmaceuticals, Inc | 4 | $84 |
| Madrigal Pharmaceuticals | 2 | $59 |
| Ferring Pharmaceuticals Inc. | 3 | $49 |
| Boston Scientific | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Orphalan Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,888 in reported general payments places this provider in the 90th percentile of 85 gastroenterology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 16 | $23,167 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 149 | $8,991 |
| MotegrityPrucalopride Succinate | 11 | $6,518 |
| Balsalazide Disodium | 13 | $4,162 |
| Omeprazole | 96 | $1,466 |
| Famotidine | 31 | $682 |
| Pantoprazole Sodium | 46 | $631 |
| Lactulose | 13 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,154 | $23,16716 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $683 | $6,51811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 85 gastroenterology providers in Rhode Island.
Other gastroenterology in Providence
- Thomas SepeProvidence$307K
- Paul AkermanProvidence$123K
- Sean FineProvidence$55K
- Alan EpsteinProvidence$36K
- Samir ShahProvidence$28K
- Lisa MuellerProvidence$25K
- Nabil ToubiaProvidence$20K
- Thaer AbdelfattahProvidence$17K
- Eric NewtonProvidence$16K
- William ChenProvidence$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.